Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Feng Chi BiotechROCO:6744 -0.68%79 Earnings Yield (Joel Greenblatt) % is 17.10% as of Jun. 2026, which is 9% below its 10-year median of 18.82. GuruFocus rates ROCO:6744 with a GF Score™ of 79/100 and a GF Value™ of NT$18.02 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 1,331 Biotechnology companies, Feng Chi Biotech ranks better than 96.62% on this metric.
Feng Chi Biotech's Enterprise Value for the quarter that ended in Jun. 2026 was NT$66.9 Mil.
Feng Chi Biotech's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was NT$11.4 Mil. Feng Chi Biotech's Earnings Yield (Joel Greenblatt) for the quarter that ended in Jun. 2026 was 17.10%.
The historical rank and industry rank for Feng Chi Biotech's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
ROCO:6744'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: 4.79 Med: 18.82 Max: 54.66
Current: 20.05
During the past 10 years, the highest Earnings Yield (Joel Greenblatt) of Feng Chi Biotech was 54.66%. The lowest was 4.79%. And the median was 18.82%.
ROCO:6744's Earnings Yield (Joel Greenblatt) % is ranked better than 96.62% of 1331
companies
in the Biotechnology industry
Industry Median: -10.03
vs ROCO:6744: 20.05
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Feng Chi Biotech's Forward Rate of Return (Yacktman) % for the quarter that ended in Jun. 2026 was -2.41%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Feng Chi Biotech (ROCO:6744) Earnings Yield (Joel Greenblatt) % Explanation
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Feng Chi Biotech Earnings Yield (Joel Greenblatt) % Related Terms
Feng Chi Biotech Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Feng Chi Biotech's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Feng Chi Biotech Earnings Yield (Joel Greenblatt) % Chart
For the Biotechnology subindustry, Feng Chi Biotech's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Feng Chi Biotech Earnings Yield (Joel Greenblatt) % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Feng Chi Biotech's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Feng Chi Biotech's Earnings Yield (Joel Greenblatt) % falls into.
Feng Chi Biotech Earnings Yield (Joel Greenblatt) % Calculation
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Feng Chi Biotechs Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
For company reported semi-annually or annually, GuruFocus only calculate annual data for Earnings Yield (Joel Greenblatt) and apply the annual figure to corresponding quarter.
What does a Earnings Yield (Joel Greenblatt) % of 17.10% mean?
Feng Chi Biotech (ROCO:6744) has a Earnings Yield (Joel Greenblatt) % of 17.10% as of Jun. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Feng Chi Biotech and its competitors. This is near median its historical median of 18.82. Over the past decade, Feng Chi Biotech's Earnings Yield (Joel Greenblatt) % has ranged from 4.79 to 54.66. According to the industry distribution chart, Feng Chi Biotech ranks #45 out of 1331 companies in the Biotechnology industry, placing it in the top 3.4%.
Is Feng Chi Biotech's Earnings Yield (Joel Greenblatt) % too high?
Feng Chi Biotech's current Earnings Yield (Joel Greenblatt) % of 17.10% is near median its 10-year median of 18.82. Over the past 10 years, this metric has ranged from a low of 4.79 to a high of 54.66. Based on the distribution chart, Feng Chi Biotech ranks #45 out of 1331 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Feng Chi Biotech has a GF Score™ of 79/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Feng Chi Biotech's Earnings Yield (Joel Greenblatt) % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Feng Chi Biotech ranks #45 out of 1331 companies for Earnings Yield (Joel Greenblatt) %. This places Feng Chi Biotech in the top 3% of its industry — outperforming the majority of peers. Historically, Feng Chi Biotech's own Earnings Yield (Joel Greenblatt) % has ranged from 4.79 to 54.66 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Biotechnology company?
A good Earnings Yield (Joel Greenblatt) % depends on the Biotechnology industry context. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Feng Chi Biotech and its competitors. Feng Chi Biotech's current Earnings Yield (Joel Greenblatt) % is 17.10%, which is near median its own 10-year median of 18.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Feng Chi Biotech stock overvalued right now?
Based on GuruFocus' analysis, Feng Chi Biotech (ROCO:6744) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$18.02, compared to a current price of NT$14.60 — trading 19% below its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is 17.10%, which is near median its 10-year median of 18.82. Feng Chi Biotech's overall GF Score™ is 79/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Feng Chi Biotech (ROCO:6744), the current Earnings Yield (Joel Greenblatt) % is 17.10% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Feng Chi Biotech (ROCO:6744) Overvalued in 2026?
Based on GuruFocus' analysis, Feng Chi Biotech stock appears to be undervalued.
The current stock price of NT$14.60 is trading 19% below its estimated GF Value™ of NT$18.02.
GuruFocus considers Feng Chi Biotech to be Modestly Undervalued.
Key valuation signals for ROCO:6744:
Earnings Yield (Joel Greenblatt) %: 17.10% (near median its 10-year median of 18.82)
GF Value™: NT$18.02 vs. price of NT$14.60 (19% below fair value)
No single metric tells the full story. See the ROCO:6744 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Feng Chi Biotech Corp provide promotion and support for clinical testing and molecular genetic medicine research related technologies. The company's products and services include clinical testing, food testing, newborn screening, prenatal screening, iron stomach, interscience, and colony counting.
79GF Score
Get the complete analysis for ROCO:6744
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6744 has been successfully added to your 
